Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Altman

Showing results (331-340 of 365) with videos related to

Pageof 37
Sort By:
Annals of Hematology|November 30, 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, et al.
Blood|October 7, 2022
PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371Hongxia Chen, Yunpeng Bai, Michihiro Kobayashi, et al.
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Blood Neoplasia|March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trialJames M Foran, Zhuoxin Sun, Selina M Luger, et al.
American Journal of Hematology|January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitorsYazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
Leukemia Research|June 18, 2013
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic deathJessica K Altman, Alfred Rademaker, Elizabeth Cull, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Acute myeloid leukemia, version 2.2013Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Molecular Cancer Research : MCR|September 27, 2023
PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL PhosphorylationHongxia Chen, Yunpeng Bai, Michihiro Kobayashi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMichael W Deininger, Neil P Shah, Jessica K Altman, et al.
Cancer|August 23, 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Hagop M Kantarjian, Kebede H Begna, Jessica K Altman, et al.
Pageof 37

Showing results (331-340 of 365) with videos related to

Sort By:
Pageof 37
Annals of Hematology|November 30, 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, et al.
Blood|October 7, 2022
PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371Hongxia Chen, Yunpeng Bai, Michihiro Kobayashi, et al.
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Blood Neoplasia|March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trialJames M Foran, Zhuoxin Sun, Selina M Luger, et al.
American Journal of Hematology|January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitorsYazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
Leukemia Research|June 18, 2013
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic deathJessica K Altman, Alfred Rademaker, Elizabeth Cull, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Acute myeloid leukemia, version 2.2013Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Molecular Cancer Research : MCR|September 27, 2023
PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL PhosphorylationHongxia Chen, Yunpeng Bai, Michihiro Kobayashi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMichael W Deininger, Neil P Shah, Jessica K Altman, et al.
Cancer|August 23, 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Hagop M Kantarjian, Kebede H Begna, Jessica K Altman, et al.
Pageof 37